Hormonal
Ceramide accumulation in specific tissues (adipose, liver, muscle) during aging and high-fat diet consumption drives insulin resistance and inflammation, linking sphingolipid metabolism to type 2 diabetes.
High levels of specific lipids called ceramides, particularly C16-ceramide, are linked to insulin resistance and type 2 diabetes. This suggests that managing lipid metabolism and reducing the production of these specific lipids (potentially through diet and exercise) may help prevent or manage insulin resistance.
Significant evidence points to roles of sphingolipids in senescence and insulin resistance... De novo Cer synthesis is involved in the increase of IL-6 and TNF-α production... CerS6-deficient mice have less C16-Cer and are protected from HFD-induced obesity and glucose intolerance.
Why this rating
Strong evidence from mouse models and human correlations (CerS6 mRNA in adipose tissue) supports the link.
Source
Role of sphingolipids in senescence: implication in aging and age-related diseases
Magali Trayssac et al. · Journal of Clinical Investigation · 2018
DOI 10.1172/jci97949
More from this paper
- Elevated intracellular ceramide levels induce cellular senescence and contribute to age-related pathologies such as insulin resistance and atherosclerosis, whereas sphingosine-1-phosphate (S1P) delays senescence and promotes cell survival.Good
- Inhibition of sphingolipid synthesis (specifically via SPT inhibition by myriocin or CerS inhibition by fumonisin B1) extends lifespan in model organisms like yeast and C. elegans, suggesting that reducing ceramide production can delay aging.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →